Clinical Outcomes of Patients with Diabetes Mellitus and Acute Myocardial Infarction Treated with Primary Angioplasty or Fibrinolysis

Overview

Journal Heart

Date 2002 Aug 16

PMID 12181218

Citations 10

Authors

L F Hsu

K H Mak

K W Lau

L L Sim

C Chan

T H Koh

S C Chuah

R Kam

Z P Ding

W S Teo

Y L Lim

Affiliations

Soon will be listed here.

Abstract

Objective: To compare the early and late outcomes of primary percutaneous transluminal coronary angioplasty (PTCA) with fibrinolytic treatment among diabetic patients with acute myocardial infarction (AMI).

Design: Retrospective observational study with data obtained from prospective registries.

Setting: Tertiary cardiovascular institution with 24 hour acute interventional facilities.

Patients: 202 consecutive diabetic patients with AMI receiving reperfusion treatment within six hours of symptom onset.

Interventions: Fibrinolytic treatment was administered to 99 patients, and 103 patients underwent primary PTCA. Most patients undergoing PTCA received adjunctive stenting (94.2%) and glycoprotein IIb/IIIa inhibition (63.1%).

Main Outcome Measures: Death, non-fatal reinfarction, and target vessel revascularisation at 30 days and one year were assessed.

Results: Baseline characteristics were similar in these two treatment groups except that the proportion of patients with Killip class III or IV was considerably higher in those treated with PTCA (15.5% v 6.1%, p = 0.03) and time to treatment was significantly longer (103.7 v 68.0 minutes, p < 0.001). Among those treated with PTCA, the rates for in-hospital recurrent ischaemia (5.8% v 17.2%, p = 0.011) and target vessel revascularisation at one year (19.4% v 36.4%, p = 0.007) were lower. Death or reinfarction at one year was also reduced among those treated with PTCA (17.5% v 31.3%, p = 0.02), with an adjusted relative risk of 0.29 (95% confidence interval 0.15 to 0.57) compared with fibrinolysis.

Conclusion: Among diabetic patients with AMI, primary PTCA was associated with reduced early and late adverse events compared with fibrinolytic treatment.

Citing Articles

The impact of diabetes mellitus and hypertension on clinical outcomes in a population of Iranian patients who underwent percutaneous coronary intervention: A retrospective cohort study.

Zibaeenezhad M, Mohammadi S, Sayadi M, Khorshidi S, Bahramali E, Razeghian-Jahromi I J Clin Hypertens (Greenwich). 2019; 21(11):1647-1653.

PMID: 31553131 PMC: 8030607. DOI: 10.1111/jch.13705.

Long-term clinical outcome of ST-segment elevation myocardial infarction patients with and without diabetes mellitus in the Zwolle trial.

Timmer J, van der Horst I, Henriques J, Thomas K, Bilo H, Hoorntje J Neth Heart J. 2015; 11(10):387-393.

PMID: 25696147 PMC: 2499982.

Impact of type 2 diabetes mellitus on hospitalization costs in older patients with acute myocardial infarction.

Fu K, Fan G, Han L, Wang X, Wang J, Wang Y Clin Interv Aging. 2014; 9:711-8.

PMID: 24812498 PMC: 4008285. DOI: 10.2147/CIA.S59802.

Hemoglobin A1c is a better predictor of prognosis following the non-ST elevation acute coronary syndrome than fasting and admission glucose.

Kmet M, Rajer B, Pernat A Wien Klin Wochenschr. 2013; 126(5-6):156-62.

PMID: 24297265 DOI: 10.1007/s00508-013-0468-2.

Impact of newly diagnosed abnormal glucose regulation on long-term prognosis in low risk patients with ST-elevation myocardial infarction: A follow-up study.

Knudsen E, Seljeflot I, Abdelnoor M, Eritsland J, Mangschau A, Muller C BMC Endocr Disord. 2011; 11:14.

PMID: 21801387 PMC: 3173358. DOI: 10.1186/1472-6823-11-14.

References

Lee K, Woodlief L, Topol E, Weaver W, Betriu A, Col J . Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators. Circulation. 1995; 91(6):1659-68. DOI: 10.1161/01.cir.91.6.1659. View

Piemontino U, Ceriello A, Di Minno G . Hemostatic and metabolic abnormalities in diabetes mellitus. The search for a link. Haematologica. 1994; 79(4):387-92. View

Fernandez A, Sequeira R, Chakko S, Correa L, De Marchena E, Chahine R . ST segment tracking for rapid determination of patency of the infarct-related artery in acute myocardial infarction. J Am Coll Cardiol. 1995; 26(3):675-83. DOI: 10.1016/0735-1097(95)00208-L. View

Califf R, White H, Van de Werf F, Sadowski Z, Armstrong P, Vahanian A . One-year results from the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO-I) trial. GUSTO-I Investigators. Circulation. 1996; 94(6):1233-8. DOI: 10.1161/01.cir.94.6.1233. View

Woodfield S, Lundergan C, Reiner J, GREENHOUSE S, Thompson M, Rohrbeck S . Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-I experience. J Am Coll Cardiol. 1996; 28(7):1661-9. DOI: 10.1016/s0735-1097(96)00397-x. View

. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med. 1997; 336(23):1621-8. DOI: 10.1056/NEJM199706053362301. View

Mak K, Moliterno D, Granger C, Miller D, White H, Wilcox R . Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol. 1997; 30(1):171-9. DOI: 10.1016/s0735-1097(97)00118-6. View

Weaver W, Simes R, Betriu A, Grines C, Zijlstra F, Garcia E . Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. JAMA. 1997; 278(23):2093-8. View

Stone G, Brodie B, Griffin J, Morice M, Costantini C, St Goar F . Prospective, multicenter study of the safety and feasibility of primary stenting in acute myocardial infarction: in-hospital and 30-day results of the PAMI stent pilot trial. Primary Angioplasty in Myocardial Infarction Stent Pilot Trial.... J Am Coll Cardiol. 1998; 31(1):23-30. DOI: 10.1016/s0735-1097(97)00439-7. View

10.

Agati L, Voci P, Hickle P, Vizza D, Autore C, Fedele F . Tissue-type plasminogen activator therapy versus primary coronary angioplasty: impact on myocardial tissue perfusion and regional function 1 month after uncomplicated myocardial infarction. J Am Coll Cardiol. 1998; 31(2):338-43. DOI: 10.1016/s0735-1097(97)00487-7. View

11.

Antoniucci D, Santoro G, Bolognese L, Valenti R, Trapani M, Fazzini P . A clinical trial comparing primary stenting of the infarct-related artery with optimal primary angioplasty for acute myocardial infarction: results from the Florence Randomized Elective Stenting in Acute Coronary Occlusions (FRESCO) trial. J Am Coll Cardiol. 1998; 31(6):1234-9. DOI: 10.1016/s0735-1097(98)00097-7. View

12.

Kleiman N, Lincoff A, Kereiakes D, Miller D, Aguirre F, Anderson K . Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators. Circulation. 1998; 97(19):1912-20. DOI: 10.1161/01.cir.97.19.1912. View

13.

Suryapranata H, van t Hof A, Hoorntje J, de Boer M, Zijlstra F . Randomized comparison of coronary stenting with balloon angioplasty in selected patients with acute myocardial infarction. Circulation. 1998; 97(25):2502-5. DOI: 10.1161/01.cir.97.25.2502. View

14.

Ribichini F, Steffenino G, Dellavalle A, Ferrero V, Vado A, Feola M . Comparison of thrombolytic therapy and primary coronary angioplasty with liberal stenting for inferior myocardial infarction with precordial ST-segment depression: immediate and long-term results of a randomized study. J Am Coll Cardiol. 1998; 32(6):1687-94. DOI: 10.1016/s0735-1097(98)00446-x. View

15.

Nunn C, ONeill W, Rothbaum D, Stone G, Okeefe J, Overlie P . Long-term outcome after primary angioplasty: report from the primary angioplasty in myocardial infarction (PAMI-I) trial. J Am Coll Cardiol. 1999; 33(3):640-6. DOI: 10.1016/s0735-1097(98)00622-6. View

16.

Stone G, Brodie B, Griffin J, Costantini C, Morice M, St Goar F . Clinical and angiographic follow-Up after primary stenting in acute myocardial infarction: the Primary Angioplasty in Myocardial Infarction (PAMI) stent pilot trial. Circulation. 1999; 99(12):1548-54. DOI: 10.1161/01.cir.99.12.1548. View

17.

Thomas K, Ottervanger J, de Boer M, Suryapranata H, Hoorntje J, Zijlstra F . Primary angioplasty compared with thrombolysis in acute myocardial infarction in diabetic patients. Diabetes Care. 1999; 22(4):647-9. DOI: 10.2337/diacare.22.4.647a. View

18.

Lincoff A, Califf R, Moliterno D, ELLIS S, Ducas J, Kramer J . Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. N Engl J Med. 1999; 341(5):319-27. DOI: 10.1056/NEJM199907293410503. View

19.

Silva J, Ramee S, White C, Collins T, Jenkins J, Nunez E . Primary stenting in acute myocardial infarction: influence of diabetes mellitus in angiographic results and clinical outcome. Am Heart J. 1999; 138(3 Pt 1):446-55. DOI: 10.1016/s0002-8703(99)70146-8. View

20.

Zijlstra F, Hoorntje J, de Boer M, Reiffers S, Miedema K, Ottervanger J . Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. N Engl J Med. 1999; 341(19):1413-9. DOI: 10.1056/NEJM199911043411901. View